If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor Venous Thromboembolism advisory service, Decision Resources is offering this exclusive analyst call entitled Assessing the Impact of the MAGELLAN Trial – What Does the Future Hold for Xarelto and Other New Anticoagulants for VTE Prevention in Medically Ill Patients? Because this analyst call will feature major findings, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. The latest installment of the clinical development program for Bayer/Johnson & Johnson’s Xarelto (rivaroxaban), which was presented at the recent 60th Annual Scientific Session of the American College of Cardiology, shed light on Xarelto’s potential use for the prevention of venous thromboembolism (VTE) in medically ill patients. The Phase III MAGELLAN study compared Xarelto to Sanofi-Aventis’s Lovenox (enoxaparin) for the prevention of VTE in acutely ill patients. While highlighting the benefits of prolonged prophylaxis in at-risk patients, MAGELLAN also emphasized the risk of bleeding with Xarelto, which was significantly higher than that seen with Lovenox. Following the release of the MAGELLAN data, Decision Resources conducted a series of interviews with thought leaders to gauge their reaction to these results and to discuss what the future might hold for new anticoagulants attempting to enter this indication. This 15-minute analyst call, presented by Decision Resources Analyst Matthew Killeen, Ph.D., will answer the following questions:
Dr. Killeen will conduct a live Q & A session after the presentation. Assessing the Impact of the MAGELLAN Trial – What Does the Future Hold for Xarelto and Other New Anticoagulants for VTE Prevention in Medically Ill Patients? April 21, 2011 at 9 a.m. U.S. Eastern Time, 3 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.
In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Matthew Killeen, Ph.D., is an analyst on the cardiovascular and metabolic disorders team at Decision Resources. Dr. Killeen is an expert on drug safety and has authored a textbook on drug-induced cardiac toxicity and co-chaired a cardiac safety meeting at the FDA. He is also the author of 19 peer-reviewed journal articles on topics including atrial fibrillation, drug safety and ventricular arrhythmias. Prior to joining the company, Dr. Killeen worked in life science business development for the London Technology Network and in neuroscience drug discovery at Eli Lilly. Dr. Killeen holds a Ph.D. in Cardiac Electrophysiology from Cambridge University and a B.Sc. (first class) in Pharmacology from the University of Leeds. He has also held research fellowships at Harvard Medical School and Massachusetts General Hospital.